Drug Profile
GS 9411
Alternative Names: GS9411; P-680Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Parion Sciences
- Developer Gilead Sciences
- Class
- Mechanism of Action Epithelial sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 10 Aug 2010 Discontinued - Phase-I for Bronchiectasis (Non-cystic fibrosis-related) in Australia (Inhalation)
- 10 Aug 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in Australia (Inhalation)
- 10 Aug 2010 Discontinued - Phase-I for Cystic fibrosis in Australia (Inhalation)